Search This Blog

Tuesday, June 15, 2021

VBL Drops After FDA Withholds Clearance for New Cancer Treatment Batches

 VBL Therapeutics Ltd. shares were down 16% to $2.26 Tuesday after the company said it was notified by the Food and Drug Administration that clearance of new VB-111 batches for use in the U.S. is currently pending the completion of a technical review evaluating the comparability of VB-111 manufacturing between different source sites.

The company's Phase 3 study is investigating ofranergene obadenovec, or VB-111, for the treatment of platinum-resistant ovarian cancer.

Until new batches are cleared, VBL expects a temporary shortage of study drug supply for the U.S.

Accordingly, recruitment of new patients in the U.S. will be temporarily paused, it said. Treatment will continue as usual for all U.S. patients currently enrolled. To date, the study has enrolled 75% of the planned 400 patients.

VBL recently amended the primary endpoint of the study based on requested changes by the company that were reviewed by the FDA. The study now includes a second, separate primary endpoint of progression free survival, in addition to the original primary endpoint of the trial, overall survival. Successfully meeting either primary endpoint is expected to be sufficient to support BLA submission.

https://www.marketscreener.com/quote/stock/VASCULAR-BIOGENICS-LTD-17053959/news/VBL-Shares-Drop-16-After-FDA-Withholds-Clearance-for-New-Cancer-Treatment-Batches-35614011/

Jounce Therapeutics Shares Rise 13% on IND Clearance for Cancer Treatment

 Jounce Therapeutics Inc. shares were up 13% to $7.88 after the company said the Food and Drug Administration has cleared its investigational new drug application for JTX-1811, an anti-CCR8 antibody, for which Gilead Sciences Inc. has exclusive rights to develop and commercialize.

The IND clearance triggers a $25 million milestone payment to Jounce.

Volume for the stock was 2 million shares at 12:50 p.m. EDT, compared to its 65-day average volume of 332,000 shares. The stock hit its 52-week high of $14.84 on March 11.

Jounce said JTX-1811, which will be referred to as GS-1811 in Gilead's pipeline, is a monoclonal antibody created by Jounce and designed to selectively deplete immunosuppressive tumor-infiltrating T regulatory cells. The target of JTX-1811 is CCR8, a chemokine receptor enriched on TITR cells. When JTX-1811 binds to CCR8, it targets TITR cells for depletion by enhancing an antibody-dependent cellular cytotoxicity mechanism.

Under the terms of their September 2020 agreement, Gilead invested $35 million in Jounce's common stock and made an $85 million upfront payment to Jounce. Jounce has led the development of JTX-1811 through IND clearance, after which Gilead now has the sole right to develop and commercialize the program.

After receiving the $25 million milestone payment, Jounce may receive up to an additional $660 million in future clinical, regulatory and commercial milestone payments and will also be eligible to receive royalties ranging from high single digit to mid-teens based upon world-wide sales.

https://www.marketscreener.com/quote/stock/JOUNCE-THERAPEUTICS-INC-33385195/news/Jounce-Therapeutics-Shares-Rise-13-on-IND-Clearance-for-Cancer-Treatment-35613955/

Social network for doctors Doximity targets $4 bln valuation in U.S. IPO

 Doximity Inc, a social network for doctors, is looking to raise nearly $536 million through a U.S. initial public offering, targeting a valuation of about $4 billion, according to a regulatory filing on Tuesday.

https://www.reuters.com/technology/social-network-doximity-targets-4-bln-valuation-us-ipo-2021-06-15/

Cuomo lifts COVID rules as New York hits 70% vaccinated

 Gov. Andrew Cuomo announced Tuesday that New York is lifting nearly all COVID-19 restrictions, after the state on Monday cleared the threshold of 70 percent of adult residents having received at least one vaccine dose.

“What does 70% mean? That means that we can now return to life as we know,” Cuomo said Tuesday.

Capacity restrictions will be lifted in most settings, and mask and cleaning protocols will also be relaxed. Restrictions will be maintained in some areas, such as nursing homes, hospitals and schools, the governor said.

“All the state-mandated restrictions are lifted on commercial social settings sports and recreation construction, manufacturing, retail buildings, all across the board we can get back to living and businesses can open, because the state mandates are gone, social gathering restrictions capacity restrictions the health screenings,  [and] the cleaning and disinfecting protocols,” said Cuomo.

The full reopening will lift capacity restrictions will be lifted in most settings.
The full reopening will lift capacity restrictions in most settings.
Alexi Rosenfeld/Getty Images

Masks will still be required on mass transit and in taxis and ride-hails since that is a CDC recommendation, but they are not required indoors anywhere anymore by the state of New York.

Cuomo made the announcement during his final COVID-19 briefing at One World Trade Center, where he handed out awards to New York union leaders at a campaign rally-style event.

Cities across the state, including in New York City, Nyack in the Hudson Valley, Syracuse and Albany will hold fireworks shows Tuesday at about 9 p.m., to celebrate the milestone, according to sources, Cuomo and reports.

“We’re no longer just surviving,” Cuomo went on. “Life is about thriving. Life is about seeing people, life is about loving, life is about celebrating life is about enjoying life is about interacting. And now we get back to living life.”

“Tonight, we’re going to light all the state assets, Empire State Building and blue and gold,” Cuomo said. “And we’re going to have fireworks all across the state of New York tonight to celebrate and honor the essential workers.”

Mayor Bill de Blasio, when asked about fireworks Tuesday morning, said he had not gotten any details about it yet. 

“We’re waiting for more information on that, obviously want to make sure that the NYPD and everyone else relevant is coordinated with,” de Blasio told a reporter at his daily briefing.

The Village of Nyack posted on social media that there would be one in its memorial park, and Lake Placid will be home to a show of its own at 9:15 p.m., according to a report.

The restriction lifting comes after Cuomo on June 7 first announced that “virtually all” state-mandated COVID-19 rules in the Empire State would soon be a thing of the past.

“When we hit 70 percent, then I feel comfortable saying to the people of this state we can relax virtually all restrictions,” he said at the time.

Following New York's reopening, nursing homes, hospitals and schools will still have capacity restrictions.
Following New York’s reopening, nursing homes, hospitals and schools will still have capacity restrictions.
Alexi Rosenfeld/Getty Images

On Monday, the governor said, citing CDC data, that 69.9 percent of New York adults had received at least one jab, which put New York a hair shy of the 70 percent benchmark.

De Blasio said Tuesday he’s “very comfortable” with the imminent complete New York state reopening.

“More than half of the city [is] on their way to full vaccination. It’s time, I’m very comfortable that it’s time,” de Blasio said during his daily press conference.

https://nypost.com/2021/06/15/andrew-cuomo-expected-to-announce-full-new-york-reopening/

COVID-19 in School Settings in First Semester of School Reopening

 

Florida, August-December 2020

Timothy Doyle, PhD; Katherine Kendrick, MPH; Thomas Troelstrup, MPH; Megan Gumke, MPH; Jerri Edwards; Shay Chapman, MBA; Randy Propper, PhD; Scott A. Rivkees, MD; Carina Blackmore, DVM, PhD

DISCLOSURES 

Morbidity and Mortality Weekly Report. 2021;70(12):437-441. 

Abstract and Introduction

Introduction

After detection of cases of COVID-19 in Florida in March 2020, the governor declared a state of emergency on March 9,* and all school districts in the state suspended in-person instruction by March 20. Most kindergarten through grade 12 (K–12) public and private schools in Florida reopened for in-person learning during August 2020, with varying options for remote learning offered by school districts. During August 10–December 21, 2020, a total of 63,654 COVID-19 cases were reported in school-aged children; an estimated 60% of these cases were not school-related. Fewer than 1% of registered students were identified as having school-related COVID-19 and <11% of K-12 schools reported outbreaks. District incidences among students correlated with the background disease incidence in the county; resumption of in-person education was not associated with a proportionate increase in COVID-19 among school-aged children. Higher rates among students were observed in smaller districts, districts without mandatory mask-use policies, and districts with a lower proportion of students participating in remote learning. These findings highlight the importance of implementing both community-level and school-based strategies to reduce the spread of COVID-19 and suggest that school reopening can be achieved without resulting in widespread illness among students in K–12 school settings.

Florida has one independent school district in each of its 67 counties. For the 2020–21 school year, 2,809,553 registered students were enrolled in approximately 6,800 public, charter, and private K–12 schools, ranging from 707 to 334,756 students per school district. In response to the COVID-19 pandemic, some school districts delayed the start of the 2020–21 academic year after suspension of in-person learning in March. Most schools resumed in-person instruction sometime during August 10–31, 2020, except those in the two largest school districts, Broward and Miami-Dade, which began remote learning in August but did not resume in-person instruction until October 9 and November 10, respectively. Statewide, as of September 24, 45% of registered students received full-time in-person instruction.

To assess the occurrence of COVID-19 in Florida schools after resumption of in-person instruction, CDC and the Florida Department of Health (FDOH) reviewed school-related cases and outbreaks during August–December 2020. County health department staff members conducted case investigations and contact tracing for all COVID-19 cases and reported data via the FDOH reportable disease surveillance system. A COVID-19 case was defined as nucleic acid amplification or antigen detection of acute infection with SARS-CoV-2 (the virus that causes COVID-19) in a symptomatic or asymptomatic person. A school-related case was defined as a COVID-19 case in a student or staff member who had been on campus for class, work, athletics, or other reasons during the 14 days preceding symptom onset or testing, and could reflect cases acquired in the school, home, or community setting. A school-based outbreak was defined as two or more epidemiologically linked school-related cases. Data regarding school start dates by district, student enrollment, and proportion of registered students receiving full-time in-person instruction were obtained from the Florida Department of Education. Information regarding temporary COVID-19–related school closures was obtained from FDOH staff members in the various counties. Data on school district mask use policies were obtained from reopening plans in each district.[1] Descriptive statistics were computed; one-way analysis of variance and simple linear regression analyses were conducted to identify factors associated with student incidence by district. Statistical analyses were performed using JMP software (version 15.1; SAS Institute). This activity was reviewed by CDC and was conducted consistent with applicable federal law and CDC policy.§

During August 10–December 21, 2020, a total of 63,654 cases of COVID-19 among persons aged 5–17 years were reported to FDOH; during the same period, 34,959 school-related COVID-19 cases were reported, including 25,094 (72%) among students and 9,630 (28%) among staff members. Therefore, among all cases reported among school-aged children, 39.4% were classified as school-related (Figure). School-related cases in children occurred in <1% (25,094 of 2,809,553) of all registered students. Among all cases in children aged 5–17 years, the median age was 13 years (interquartile range = 9–15 years) and did not differ between cases that were and were not school-related. Among school-related cases, 101 hospitalizations and no deaths were reported among students, and 219 hospitalizations and 13 deaths were identified among school staff members. Among the 13 staff members who died, nine had risk factors for severe outcomes, including obesity (seven), age >60 years (four), and other chronic conditions (four); some reported probable exposures outside the school setting, including within the household.

Figure.

Weekly school-related COVID-19 cases reported among students, as a proportion of overall cases in children aged 5–17 years and in the general population — Florida, August–December 2020*
*Week beginning December 21 is a partial week, only including December 21, 2020.

Contact tracing investigations identified 86,832 persons who had close school setting contact with persons with cases of school-related COVID-19; among these, 37,548 (43%) received testing. Overall, 10,092 (27% of contacts who were tested) received a positive SARS-CoV-2 test result while in quarantine. Testing of symptomatic persons was encouraged; however, 11% of school contacts who had COVID-19–symptoms** were not tested.

A total of 695 school-based outbreaks were identified in 62 (93%) of 67 school districts, involving 4,370 total cases, for a statewide average of 6.3 COVID-19 cases per outbreak. Therefore, <11% (695 of 6800) of schools reported an outbreak. A subset of 562 (81%) outbreaks with additional information was further analyzed; 110 (20%) of these outbreaks were associated with activities outside the classroom setting, including sports (91), nonschool–sponsored social gatherings (12), or transportation to school (four). The most frequent extracurricular sports-related outbreaks involved football (27), basketball (14), volleyball (nine), wrestling (eight), dance (eight), cheerleading (seven), and soccer (six). Sports-related outbreaks were larger on average than were nonsports–related outbreaks (mean = 6.0 cases versus 4.1 cases; p<0.01). The four largest sports-related outbreaks involved two wrestling events (58 and 27 cases) and two football events (18 and 17 cases). Most sports-related outbreaks involved high school grade levels.

Through December 18, 2020, a total of 28 schools in 12 counties closed temporarily because of COVID-19, with a median closure duration of 4 days (range = 1–14 days); 16 (57%) closures occurred in public schools, nine (32%) in private schools, and three (11%) in charter schools. Partial closures of one or more classrooms, but not the entire school, occurred in 226 schools in 38 counties; 88% of these partial closures occurred in public schools, 8% in private, and 4% in charter schools. Elementary school grades accounted for 75% of partial closures.

Descriptive statistics for the 67 county-based school districts indicated that a median of 70% of students were attending school and receiving full-time in-person instruction as of September 24 (range = <1% [Miami-Dade and Broward] to 94% [Baker]) (Table 1). The median incidence among registered students was 1,280 per 100,000 students, ranging from 394 to 3,200 among counties.

Factors identified in bivariate analysis associated with student case rate by district were county population size, school opening during the first week, district reopening plans that included mandatory mask use, proportion of students attending in-person instruction, and the background case rate per county during August 10–December 21 (Table 2). Higher mean student case rates were reported from counties with the lowest population, districts opening school during August 10–14, and districts that did not mandate mask use in their reopening plans, compared with rates in larger counties, districts opening after August 16, and those with mask mandates. The background cumulative disease incidence during August 10–December 21 in each county was positively correlated with the incidence among students. The proportion of students, by district, attending full-time in-person instruction also positively correlated with the student case rate. In general, smaller counties resumed classes earlier, had a higher proportion of students attending in-person instruction, were less likely to mandate universal mask use in schools, and had higher student incidences (2,212 per 100,000 in the lowest county population quartile versus 970 in the highest).

Discussion

Although COVID-19 can and does occur in school settings, the results of these analyses indicate that in Florida, 60% of COVID-19 cases in school-aged children were not school-related, <1% of registered students were identified as having school-related COVID-19, and <11% of K–12 schools reported outbreaks. These findings add to a growing body of evidence suggesting that COVID-19 transmission does not appear to be demonstrably more frequent in schools than in noneducational settings.[2] Temporal trends in the United States also indicate that among school-aged children, school-based transmission might be no higher than transmission outside the school setting;[3,4] the limited in-school transmission observed in Florida has also been observed in other states[5] and countries.[6]

Success in preventing the introduction of SARS-CoV-2 into schools depends upon controlling community transmission and adhering to mitigation measures in schools, particularly masking, physical distancing, testing, and increasing room air ventilation.[2,4,7] Where feasible, supporting family choice for remote versus in-person learning likely reduces in-school crowding and facilitates better physical distancing in schools. In Florida, a large proportion of school-related outbreaks was observed among social gatherings and extracurricular sporting activities. Household transmission and social gatherings might pose a higher risk for infection among school-aged children than does school attendance.[8] School sports and other extracurricular activities in which masking and physical distancing are difficult or impossible to achieve should be postponed, particularly during periods of high community transmission.[2,9]

The findings in this report are subject to at least six limitations. First, because data on the number of teachers and staff members statewide or by county were not available, rates of total school-related cases could not be calculated; instead, the number of student cases per 100,000 registered students was used. Second, screening testing was generally not done in most schools, therefore, asymptomatic infections might have been underascertained. Third, classification of school-related cases, contacts, and outbreaks was dependent on thorough case interviews and might have been incomplete, relative to the overall number of cases in school-aged children. Fourth, although the operational definition used for school-related cases was likely sensitive, it does not ensure that all persons with school-related cases acquired infection in the school setting because infections might have been acquired elsewhere. Fifth, limited data were available at the school district level on some mitigation measures, such as mask use in schools, so these mitigation measures could not be fully assessed. Finally, results should be interpreted with caution because most students in the largest school districts did not resume in-person education for the first part of the analysis period.

These findings provide further evidence that resumption of school can likely be achieved without the rapid disease spread observed in congregate living facilities or high-density worksites. Both community-level and school-based measures to prevent spread of disease are essential to reduce SARS-CoV-2 transmission in school settings.[10]

https://www.medscape.com/viewarticle/948229

The COVID Fertility Issue We Should Be Worried About

 Welcome to Impact Factor, your weekly dose of commentary on a new medical study. I'm Dr F. Perry Wilson of the Yale School of Medicine.

There's a meme flying around the interwebs that COVID vaccines might render young people infertile. Taken on its own, this may seem like run-of-the-mill antivax fearmongering — and it is, but this one seems to have some legs. In fact, a UK survey found that one quarter of young women would decline the vaccine, citing concerns about fertility.

This is actually a sort of old vaccine trope. It's been trotted out — without any evidence — for the polio vaccine and the HPV vaccine. And I get why it's so powerful. Fertility is obviously a huge issue, a basic human function. But it also immediately conjures up the long term: Sure, I may be protected from COVID today, but what if I want to have kids 15 years from now and find out I can't? The Handmaid's Tale stuff. Disturbing.

So I want to show how this thing got started, but more importantly, I want to make an argument: that if you really want to worry about fertility, you should worry about SARS-CoV-2 more than the SARS-CoV-2 vaccine.

You can trace the earliest emergence of this idea to two guys: Wolfgang Wodarg, a physician and German politician; and Michael Yeadon, an ex-Pfizer scientist. Yeadon's Pfizer link lent him credibility, though a perusal of his Twitter account (now deleted) suggests that he was not the best COVID prognosticator. This was tweeted a couple months before the UK's much more deadly second wave.


 

In any case, their argument centered around the similarity between the spike protein that the vaccines code for and syncytin-1, a human protein critical for placental development. Syncytin-1 is known as an endogenous retroviral element — basically, code in our DNA that came from an old virus. We have a bunch of these, actually. This one probably got in there around 25 million years ago and conferred some selective advantage, leading it to hang around.

The question: Is syncytin-1 similar enough to the spike protein of coronavirus that cross-reactive antibodies might attack the placenta?

The answer, at least according to the geneticists and immunologists I polled, is not really.

They are dramatically different proteins.


 

The spike protein is complex, with 1273 amino acids. Syncytin-1 has 538 amino acids. An alignment search suggests about a 7% overlap. Here's a sample of the sequences to give you a sense of what that means; syncytyin-1 is red, and the matches with spike protein are in red underneath.


But I'm told that this amount of homology is not surprising. More importantly, it's not really the degree of overlap that matters to figure out if an antibody will be cross-reactive. It's actually quite hard to predict and has to do with 3D topology of proteins and stuff.

If you want to figure out whether an antibody will be cross-reactive, just measure it. That's what Akiko Iwasaki here at Yale did. Her lab tested serum of women with COVID-19 and found no antibodies that bound to syncytin-1.

We also have the empirical data from the vaccine trials that showed no difference in miscarriage rates between women who became pregnant in the vaccine groups vs the placebo groups. We also now have data on over 100,000 pregnant women who have received the vaccine in the US. So far, no safety signals have emerged. This fertility theory just doesn't hold up to reality.

And not to be pedantic here, but even if there was homology between the spike protein and a human protein, the virus itself has the spike protein too, as well as a bunch of other proteins not present in the vaccine that might also have antibody cross-reactivity problems. Maybe it's better not to get COVID at all?

In fact, if it's sterility you're worried about, I honestly think there's more to be concerned about with the virus itself than the vaccine. Here's why.

The cellular receptor for the coronavirus is ACE2. Enter that into a protein expression atlas of your choice and look where ACE2 is most robustly expressed.

Source: The Human Protein Atlas

Nasopharynx and bronchus — no surprises there. But also, testis and placenta. In fact, ACE2 is robustly expressed on Sertoli cells, which are the support cells that help sperm be produced.

Source: The Human Protein Atlas

This has led to multiple papers (all hypothetical at this point) speculating that SARS-CoV-2 infection may impact male fertility.

To be fair, we haven't seen much evidence of this either. I have found a total of one paper — a case report — suggesting that COVID infection hurt a man's sperm count.

But the point is this: The vaccines prime your immune system against the spike protein. But so does COVID. And COVID, unlike the vaccine, can actually infect cells and kill them — including, potentially, cells that are important for reproduction.

The anti-vaccination crowd wants to argue that there is biologic plausibility for a COVID vaccine–infertility link. If that's our standard for evidence, there is a heck of a lot more plausibility for a COVID-infertility link. But as I've said many times before, biologic plausibility is just the start of research. Empirical data are necessary in the end. There's enough empirical data to conclude that it is highly unlikely that the vaccines will have any effect on fertility. It's pretty unlikely that COVID itself will have an effect either, but it seems to me like that possibility deserves some deeper investigation.

F. Perry Wilson, MD, MSCE, is an associate professor of medicine and director of Yale's Clinical and Translational Research Accelerator. His science communication work can be found in the Huffington Post, on NPR, and here on Medscape. He tweets @fperrywilson and hosts a repository of his communication work at www.methodsman.com.


https://www.medscape.com/viewarticle/952641

Nightstar becomes nightmare, but Biogen has bigger fish to fry

 It is just as well that Aduhelm was approved, adding $18bn to Biogen’s market cap, or the group’s business development decisions would now be coming under fire. Yesterday’s failure of the second of two gene therapies Biogen got from Nightstar has rendered that $877m acquisition, done in 2019, worthless.

$877m is chump change against what analysts think Aduhelm will sell, and today’s disappointing depression data for the Sage-originated zuranolone similarly pale into insignificance for Biogen. But the failure shows how difficult targeting eye diseases with gene therapy is proving to be, and vindicates Nightstar’s decision to sell itself at a seemingly undemanding valuation.

The Nightstar deal was priced 14% lower than where the target’s stock had been trading just six months previously (Nightstar gives Biogen a cheap way to expand in gene therapy, March 4, 2019). Thus the sale looked questionable, but it was accepted as a compromise between the peak of investor euphoria and a realistic minimum necessary to get a deal done.

Flattering

Reality has turned out far more flattering for those managing the sale of Nightstar, which effectively had two R&D assets. The first of those, BIIB112 for X-linked retinitis pigmentosa, failed in its phase 1/2 Xirius study last month.

Yesterday came news that the second, BIIB111 for the rare inherited retinal disease choroideremia, was also going nowhere. The phase 3 Star trial failed its primary endpoint, which had aimed to show that BIIB111 could improve best corrected visual acuity at 12 months by 15 letters or more versus control. Biogen added that key secondary measures were also missed.

Neither BIIB111, known under the INN timrepigene emparvovec, nor BIIB112 (cotoretigene toliparvovec) had carried significant sellside consensus forecasts, and their failures do not move the needle in terms of Biogen’s investment case. This is especially true now that in Aduhelm Biogen has a potential Alzheimer’s disease blockbuster on its hands.

Tough

Still, it will not go unnoticed that eye diseases are proving tough for gene therapy. The recent setback for Adverum’s ADVM-022 concerned not lack of efficacy but a toxicity scare, while Regenxbio’s RGX-314, like ADVM-022 a gene therapy for wet AMD, spent time on clinical hold.

Investor confidence is waning fast, something the Nightstar disappointments will do nothing to help. For instance Applied Genetic Technologies, a major player in gene therapies for rare ocular disorders, is today worth under $200m; its lead asset, AGTC-501, has failed to excite.

AGTC-501 is about to start a pivotal trial in X-linked retinitis pigmentosa, as is Meiragtx’s Johnson & Johnson-partnered MGT009. 4D Molecular is also active in X-linked retinitis pigmentosa and wet AMD, and is worth $780m, down 20% this year.

In choroideremia Roche is developing two gene therapies: 4D-110, licensed from 4D Molecular, and RG6367, acquired along with Spark in 2019. BIIB111’s failure leaves the way clear for these, now biopharma’s most advanced choroideremia gene therapies; the former’s phase 1 trial should read out next year, but the latter hardly appears in sellside models any more.


https://www.evaluate.com/vantage/articles/news/trial-results/nightstar-becomes-nightmare-biogen-has-bigger-fish-fry